Feedback
Imatinib
3000539
Ordering Recommendation

Optimize dose, detect variable pharmocokinetics, and monitor patient adherence.

Mnemonic
IMATINIB
Methodology
Immunoturbidimetry
Performed
Tue, Fri
Reported
1-5 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Prior to testing patient should have had uninterrupted imatinib therapy for at least 29 days with no change in dose or treatment for at least 8 days. Blood draw should be performed immediately prior to the next scheduled dose. 
Collect
Plasma, Pre-dose (Trough) Draw - At a Steady State Concentration, in K2EDTA (Lavender or Pink) or Lithium Heparin (Green) 
Specimen Preparation
Separate from cells within 48 hours of collection. Centrifuge the whole blood for a minimum of 10 minutes to separate the plasma from cells. Carefully draw off the plasma starting from the top of the plasma layer, avoiding the cell layer (contamination of plasma with blood cells may interfere with results). Transfer 1 mL plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL) 
Storage/Transport Temperature
Refrigerated 
Unacceptable Conditions
Whole blood, gel separator tubes, light blue (citrate), or yellow top tubes. 
Remarks
 
Stability
Ambient: 7 days; Refrigerated: 30 days; Frozen: 30 days 
Reference Interval
500-1999 ng/mL
Interpretive Data
The therapeutic range is based on plasma pre-dose (trough) draw at steady-state concentration. Concentrations above 1000 ng/mL in chronic myelogenous leukemia (CML) patients, and above 1100 ng/mL in gastrointestinal stromal tumor (GIST) patients are statistically associated with an improved response.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Hotline History
View Hotline History
Components
Component Test Code*Component Chart NameLOINC
3000540Imatinib
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Gleevec
  • Glivac
  • Imatinib Mesylate